The Infectious Disease Clinic and Center for Gastroenterology at the Karolinska University Hospital in Huddinge and Solna, Sweden, will be the setting for a phase I/II clinical study of a hepatitis C virus (HCV) vaccine.
Twelve patients are expected to be enrolled in the trial, divided into three dose groups administered with increases doses of the drug, called ChronVac-C, and manufactured by Swedish pharmaceutical company Tripep AB.
The treatment has so far been safe and tolerable, with samples taken before, during and after treatment showing that an immune response against HCV became detectable after treatment, where there had not been one before.
The vaccine is intended to be a therapeutic DNA vaccine, given to individuals already infected with HCV, to help the body get rid of the infection by stimulating its own immune response.
Karolinska University Hospital is one of the leading hospitals in Sweden, a result of the merging of the Huddinge University Hospital, Inc and Karolinska Hospital. A teaching hospital, Karolinska University Hospital is one of the largest in Scandinavia, with 1,600 beds and 14,500 staff.